Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“
Medexus”) (TSXV: MDP) (OTCQX: MEDXF)
(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class .
Medexus Pharmaceuticals IncFebruary 2, 2021 GMT
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” and together with Medexus, the “Company”) entered into a Commercialization and Supply Agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. (“medac”), pursuant to which medac has granted Medexus Pharma an excl
Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology
Published 01 February 2021
I have previously discussed the use of antibody-drug conjugates for selective tumor cell intensification of urothelial carcinoma therapy in a Urotoday Clinical Trials Portal article.
1 Similarly, I’ve also focused on enfortumab vedotin before, and enfortumab vedotin is now FDA approved on the accelerated pathway for patients with locally advanced or metastatic urothelial carcinoma in the post-platinum chemotherapy and post-PD-(L1) antibody therapy setting.
2 Yet, even as new data continues to emerge on the use of enfortumab vedotin in various settings, we should take time to evaluate the development of other promising antibody-drug conjugates.
Share this article
Share this article
SAN FRANCISCO, Jan. 28, 2021 /PRNewswire/ Solv, the leading digital healthcare platform for convenient care, today announced Solv for Vaccines, a scalable scheduling and logistics solution that enables hospitals, urgent care clinics and public health organizations to power high volume COVID-19 vaccination sites in every community across the country.
Solv for Vaccines Command Center
New tech solution is accelerating vaccine delivery for hospitals, clinics, and government health organizations.
The world has embarked on one of the largest mass vaccination campaigns in human history. Accelerating vaccinations is critical to saving lives and reopening the country and economy, but the initial roll out has proven that quickly vaccinating millions of people is a tough logistical challenge for healthcare organizations and their partners in the public health community. Traditional healthcare technology and EMRs were not built to handle high volume
6 Steps to Take After a Kidney Cancer Diagnosis
A kidney cancer diagnosis can be life-altering news, but there are ways you can take control. Find out what you can do to get organized, get informed, and get the support you need.
January 26, 2021
From where to go for reliable information about kidney cancer to which healthcare professionals to include in your treatment team, here’s what you can do to optimize your care after your diagnosis.
iStock (2)
If you’ve been recently diagnosed with kidney cancer, you’re not alone: More than 76,000 people are expected to be diagnosed with kidney cancer in 2021, according to the American Cancer Society (ACS). And if you feel overwhelmed by your diagnosis, it’s important to keep in mind that this is a normal reaction. “A kidney cancer diagnosis is really like a trauma,” says Evan T. Hall, MD, an oncologist who specializes in skin cancer and kidney cancer at the Seattle Cancer Care Alliance and an assistant professor at the Univer